Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI
Sarcopenia · Chronic Heart Failure
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 18 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 249 Actual
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
The loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. The purpose was to identify in these patients signs of sarcopenia for a better management.
Read the full description
Age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. The concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type II. In fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. The diagnosis is assessed by the weak muscle mass and the muscle strength and function. A description of these muscle parameters has been described in a study of 200 patients with NYHA class II-III and showed that 19,5 % have a decrease in muscle mass. They also showed that these patients have a lower functional ability. These findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Major patients (\>18 years)
- Men or women
- Hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of Clermont-Ferrand or
- Patients with chronic heart failure in charge in the hospital of Clermont-Ferrand or convalescence in the pneumocardiological clinic of Durtol
Exclusion Criteria:
- Patient not affiliated to social security
- Inability to understand the information consent letter
- Not having signed informed consent
- Has a mental or legal incapacitation and is unable to provide informed consent.
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not randomized
- Masking
- No masking
Heart failure patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
Diagnostic Test: Assessment of sarcopenia prevalence
TAVI patients
The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
Diagnostic Test: Assessment of sarcopenia prevalence
Assessment of sarcopenia prevalence DIAGNOSTIC_TEST
Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Bioimpedance analysis data
Time frame: at day 1
Fat-free mass and body fat mass will be combined to report BMI in Kg/m2
Short physical performance battery
Time frame: at day 1
Balance test, 4-min walking test, 5 times getting-up test
Handgrip test
Time frame: at day 1
Not reported in this registry record.
Secondary measures
Blood draw for serum creatinine in umol/L
Time frame: at day 1
Measure of inflammation
CRP in mg/L
Time frame: at day 1
Measure of inflammation
platelets in Giga/L
Time frame: at day 1
Measure of inflammation
complete blood count CBC (white blood cells in Giga/L and red blood cells in Tera/L)
Time frame: at day 1
Measure of inflammation
urea in mmol/L
Time frame: at day 1
Measure of inflammation
albumin in g/L
Time frame: at day 1
Measure of inflammation
NT-ProBNP in ng/L
Time frame: at day 1
Measure of inflammation
Electrocardiogram
Time frame: at day 1
Parameter which may interfere with sarcopenia
Trans-thoracic echography
Time frame: at day 1
Parameter which may interfere with sarcopenia
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
CHU Clermont-FerrandClermont-Ferrand, Auvergne, FranceStatus unknown
Study team and timeline
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Study start
- Nov 3, 2014 Actual
- Primary completion
- Nov 30, 2018 Actual
- Study completion
- Dec 31, 2018 Actual
- First posted
- May 15, 2017 Actual
- Last updated
- Nov 9, 2026 Actual
Official study contacts
No central contact is listed. Check the locations and the official record.
Official study title
Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before Transcatheter Aortic Valve Implantation
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 9, 2026